Medavir

Medivir is a Swedish clinical-stage pharmaceutical company focused on developing innovative cancer therapies and treatments for rare diseases. The company leverages its deep expertise in protease inhibitor design and nucleotide/nucleoside science to create targeted therapies for areas with high unmet medical needs. Its lead program, fostroxacitabine bralpamide (fostrox), is a liver-directed nucleotide prodrug currently in Phase 1b/2a development for hepatocellular carcinoma. Medivir also maintains a portfolio of partnered and out-licensed assets, including remetinostat for skin cancers and birinapant for solid tumors. Headquartered in Huddinge, Sweden, the company is publicly traded on Nasdaq Stockholm.